Table 2.

Multivariate analysis for predictors of significant liver inflammation and fibrosis

	Clinical parameter	Significant inflammation			Significant fibrosis
		OR	95%CI	p-value	OR	95%CI	p-value
HBeAg-positive	Age
	< 30 years	1.000			1.000
	≥ 30 years	0.984	0.547–1.773	0.958	1.941	1.143–3.297	0.014
	Sex
	Female	1.000			1.000
	Male	1.044	0.533–2.045	0.900	0.896	0.497–1.617	0.716
	ALT
	< 1 × ULN	1.000			1.000
	1–2 × ULN	1.259	0.661–2.396	0.483	0.912	0.495–1.679	0.768
	≥ 2 × ULN	9.385	4.880–18.052	< 0.001	5.749	3.420–9.666	< 0.001
	PLT	0.993	0.988–0.998	0.004	0.993	0.988–0.997	0.001
HBeAg-negative	Age
	< 30 years	1.000			1.000
	≥ 30 years	0.820	0.418–1.608	0.563	0.999	0.539–1.851	0.996
	Sex
	Female	1.000			1.000
	Male	2.254	0.923–5.504	0.065	1.553	0.659–3.659	0.314
	ALT
	< 1 × ULN	1.000			1.000
	1–2 × ULN	1.798	0.681–4.752	0.237	1.740	0.700–4.326	0.234
	≥ 2 × ULN	4.328	2.071–9.042	< 0.001	3.555	1.847–6.844	< 0.001
	PLT	0.992	0.987–0.998	0.007	0.991	0.986–0.996	0.001

Binary logistic regression analysis with a forward approach was used for Multivariate analysis

The ULN for ALT was 40U/L

The serum HBV markers, including HBV DNA, Hepatitis B surface antigen (HBsAg), Hepatitis B e antigen (HBeAg), were not subjected to analysis, due to the lack of quantitative data. Between 1999 and 2003, most individuals only underwent qualitative testing of HBV markers

ULN Upper limit of normal, PLT Platelet, ALT Alanine transaminase, CI Confidence interval, OR Odds ratio